糖尿病与肺结核共病的临床研究进展

doi:10.19983/j.issn.2096-8493.20210121

摘要/Abstract

摘要：

糖尿病在内科系统疾病中是临床常见病,结核病是发展中国家危害人民生命健康安全的重要传染病,在糖尿病患者中结核病的患病率较一般人群高。糖尿病与肺结核共病(diabetes comorbidity with tuberculosis,DM-PTB)严重威胁人类健康,易形成糖尿病和肺结核的“恶性循环”,为二者的公共卫生防治带来了“双重挑战”。因此,作者针对DM-PTB的患病率、可能的发病机制、流行病学变化、临床特点、筛查与诊断、抗结核和降血糖的临床治疗策略与预防管理措施进行综述,为DM-PTB的临床诊断和治疗,以及疾病控制和预防提供科学的参考依据和可行性建议。

关键词: 糖尿病, 结核,肺, 共病现象, 综合治疗, 疾病管理

Abstract:

Diabetes is a common clinical medical diseases, while tuberculosis is an important infectious disease that endangers people’s lives and health in developing countries. The prevalence of tuberculosis in diabetic patients is higher than the general population. Diabetes comorbidity with tuberculosis (DM-PTB) is a serious threat to human health and is prone to form a “vicious circle”, posing “dual challenges” to the public health prevention and control for both of the diseases. Therefore, we reviewed the prevalence, possible pathogenesis, epidemiological trends, clinical features, screening and diagnosis, anti-tuberculosis and anti-diabetic clinical treatment strategies and preventive management measures of DM-PTB, to provide scientific reference and feasible suggestion for the clinical diagnosis and treatment, disease control and prevention of it.

Key words: Diabetes mellitus, Tuberculosis,pulmonary, Comorbidity, Comprehensive treatment, Disease management

中图分类号:

R521
R587.2

董航, 杜映荣. 糖尿病与肺结核共病的临床研究进展[J]. 结核与肺部疾病杂志, 2022, 3(1): 65-69. doi: 10.19983/j.issn.2096-8493.20210121

DONG Hang, DU Ying-rong. Progress in clinical research on comorbidity of pulmonary tuberculosis and diabetes mellitus[J]. Journal of Tuberculosis and Lung Disease, 2022, 3(1): 65-69. doi: 10.19983/j.issn.2096-8493.20210121

参考文献 48

[1]	World Health Organization. Diabetes. Geneva: World Health Organization, 2021.
[2]	周林, 刘二勇. 结核病诊断标准解读. 寄生虫病与感染性疾病, 2019, 17(1):7-9.
[3]	World Health Organization. Global tuberculosis report 2021. Geneva: World Health Organization, 2021.
[4]	Van Crevel R, Critchley JA. The Interaction of Diabetes and Tuberculosis: Translating Research to Policy and Practice. Trop Med Infect Dis, 2021, 6(1):8. doi: 10.3390/tropicalmed6010008. doi: 10.3390/tropicalmed6010008
[5]	Al-Rifai RH, Pearson F, Critchley JA, et al. Association between diabetes mellitus and active tuberculosis: A systematic review and meta-analysis. PLoS One, 2017, 12(11):e0187967. doi: 10.1371/journal.pone.0187967. doi: 10.1371/journal.pone.0187967 URL
[6]	Lee MR, Huang YP, Kuo YT, et al. Diabetes Mellitus and Latent Tuberculosis Infection: A Systematic Review and Metaanalysis. Clin Infect Dis, 2017, 64(6):719-727. doi: 10.1093/cid/ciw836. doi: 10.1093/cid/ciw836
[7]	Scriba TJ, Coussens AK, Fletcher HA. Human Immunology of Tuberculosis. Microbiol Spectr, 2017, 5(1). doi: 10.1128/microbiolspec.TBTB2-0016-2016. doi: 10.1128/microbiolspec.TBTB2-0016-2016
[8]	Pan SC, Ku CC, Kao D, et al. Effect of diabetes on tuberculosis control in 13 countries with high tuberculosis: a modelling study. Lancet Diabetes Endocrinol, 2015, 3(5):323-330. doi: 10.1016/s2213-8587(15)00042-x. doi: 10.1016/s2213-8587(15)00042-x URL
[9]	Hensel RL, Kempker RR, Tapia J, et al. Increased risk of latent tuberculous infection among persons with pre-diabetes and diabetes mellitus. Int J Tuberc Lung Dis, 2016, 20(1):71-78. doi: 10.5588/ijtld.15.0457. doi: 10.5588/ijtld.15.0457 pmid: 26688531
[10]	Critchley JA, Restrepo BI, Ronacher K, et al. Defining a Research Agenda to Address the Converging Epidemics of Tuberculosis and Diabetes: Part 1: Epidemiology and Clinical Management. Chest, 2017, 152(1):165-173. doi: 10.1016/j.chest.2017.04.155. doi: S0012-3692(17)30730-4 pmid: 28434936
[11]	寇廷艳. 2型糖尿病并发活动性肺结核特征及危险因素研究. 青岛:青岛大学, 2018.
[12]	王胜难, 郑亦慧, 史琰琰, 等. 上海市普陀区2012—2016年户籍人口糖尿病患者并发肺结核的情况及影响因素分析. 复旦学报(医学版), 2021, 48(1):55-58. doi: 10.3969/j.issn.1672-8467.2021.01.008. doi: 10.3969/j.issn.1672-8467.2021.01.008
[13]	Ping PA, Zakaria R, Islam MA, et al. Prevalence and Risk Factors of Latent Tuberculosis Infection (LTBI) in Patients with Type 2 Diabetes Mellitus (T2DM). Int J Environ Res Public Health, 2021, 18(1). doi: 10.3390/ijerph18010305. doi: 10.3390/ijerph18010305
[14]	Kou T, Wang Q, Lv W, et al. Poor Sleep Quality Is Associated with a Higher Risk of Pulmonary tuberculosis in Patients with a Type 2 Diabetes Mellitus Course for More than 5 Years. Jpn J Infect Dis, 2019, 72(4):243-249. doi: 10.7883/yoken.JJID.2018.099. doi: 10.7883/yoken.JJID.2018.099 URL
[15]	董春江. 膳食及行为习惯对中老年糖尿病并发肺结核患病风险影响的研究. 青岛:青岛大学, 2019.
[16]	Segura-Cerda CA, López-Romero W, Flores-Valdez MA. Changes in Host Response to Mycobacterium tuberculosis Infection Associated With Type 2 Diabetes: Beyond Hyperglycemia. Front Cell Infect Microbiol, 2019, 9:342. doi: 10.3389/fcimb.2019.00342. doi: 10.3389/fcimb.2019.00342 URL
[17]	Restrepo BI, Twahirwa M, Rahbar MH, et al. Phagocytosis via complement or Fc-gamma receptors is compromised in monocytes from type 2 diabetes patients with chronic hyperglycemia. PLoS One, 2014, 9(3):e92977. doi: 10.1371/journal.pone.0092977. doi: 10.1371/journal.pone.0092977 URL
[18]	Ayelign B, Negash M, Genetu M, et al. Immunological Impacts of Diabetes on the Susceptibility of Mycobacterium tuberculosis. J Immunol Res, 2019, 2019:6196532. doi: 10.1155/2019/6196532. doi: 10.1155/2019/6196532
[19]	Kumar NP, Moideen K, George PJ, et al. Coincident diabetes mellitus modulates Th1-, Th2-, and Th17-cell responses in latent tuberculosis in an IL-10- and TGF-β-dependent manner. Eur J Immunol, 2016, 46(2):390-399. doi: 10.1002/eji.201545973. doi: 10.1002/eji.201545973 URL
[20]	Banchereau J, Pascual V, O’Garra A. From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol, 2012, 13(10):925-931. doi: 10.1038/ni.2406. doi: 10.1038/ni.2406 pmid: 22990890
[21]	Huangfu P, Ugarte-Gil C, Golub J, et al. The effects of diabetes on tuberculosis treatment outcomes: an updated systematic review and meta-analysis. Int J Tuberc Lung Dis, 2019, 23(7):783-796. doi: 10.5588/ijtld.18.0433. doi: 10.5588/ijtld.18.0433 pmid: 31439109
[22]	Ruslami R, Nijland HM, Adhiarta IG, et al. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob Agents Chemother, 2010, 54(3):1068-1074. doi: 10.1128/AAC.00447-09. doi: 10.1128/AAC.00447-09 pmid: 20038625
[23]	Tong X, Wang D, Wang H, et al. Clinical features in pulmonary tuberculosis patients combined with diabetes mellitus in China: An observational study. Clin Respir J, 2021, 15(9):1012-1018. doi: 10.1111/crj.13405. doi: 10.1111/crj.13405 URL
[24]	Evelina L, Alina M, Stela K, et al. The predictors of pulmonary tuberculosis in Xpert MBT/Rif positive and resistant assay patients with diabetes mellitus. Moldovan Med J, 2018, 61(2):1379-1385. doi: 10.1111/tmi.12198.30. doi: 10.1111/tmi.12198.30
[25]	Kim J, Lee IJ, Kim JH. CT findings of pulmonary tuberculosis and tuberculous pleurisy in diabetes mellitus patients. Diagn Interv Radiol, 2017, 23(2):112-117. doi: 10.5152/dir.2016.16157. doi: 10.5152/dir.2016.16157 URL
[26]	Mota M. Pulmonary Tuberculosis Characteristics in a Patient with Type 2 Diabetes Mellitus. J Diabetes, 2019, 26(1):73-77.
[27]	Grint D, Alisjhabana B, Ugarte-Gil C, et al. Accuracy of diabetes screening methods used for people with tuberculosis, Indonesia, Peru, Romania, South Africa. Bull World Health Organ, 2018, 96(11):738-749. doi: 10.2471/blt.17.206227. doi: 10.2471/blt.17.206227 URL
[28]	Jeon CY, Harries AD, Baker MA, et al. Bi-directional screening for tuberculosis and diabetes: a systematic review. Trop Med Int Health, 2010, 15(11):1300-1314. doi: 10.1111/j.1365-3156.2010.02632.x. doi: 10.1111/j.1365-3156.2010.02632.x URL
[29]	Lyon SM, Rossman MD. Pulmonary Tuberculosis. Microbiol Spectr, 2017, 5(1). doi: 10.1128/microbiolspec.TNMI7-0032-2016. doi: 10.1128/microbiolspec.TNMI7-0032-2016
[30]	Kim J, Lee IJ, Kim JH. CT findings of pulmonary tuberculosis and tuberculous pleurisy in diabetes mellitus patients. Diagn Interv Radiol, 2017, 23(2):112-117. doi: 10.5152/dir.2016.16157. doi: 10.5152/dir.2016.16157 URL
[31]	Xia LL, Li SF, Shao K, et al. The correlation between CT features and glycosylated hemoglobin level in patients with T2DM complicated with primary pulmonary tuberculosis. Infect Drug Resist, 2018, 11:187-193. doi: 10.2147/idr.S146741. doi: 10.2147/IDR.S146741 pmid: 29430189
[32]	Wang JY, Lee MC, Shu CC, et al. Optimal duration of anti-TB treatment in patients with diabetes: nine or six months? Chest, 2015, 147(2):520-528. doi: 10.1378/chest.14-0918. doi: 10.1378/chest.14-0918 URL
[33]	Alfarisi O, Mave V, Gaikwad S, et al. Effect of Diabetes Mellitus on the Pharmacokinetics and Pharmacodynamics of Tuberculosis Treatment. Antimicrob Agents Chemother, 2018, 62(11). doi: 10.1128/aac.01383-18. doi: 10.1128/aac.01383-18
[34]	Wang JY, Lee MC, Shu CC, et al. Optimal duration of anti-TB treatment in patients with diabetes: nine or six months? Chest, 2015, 147(2):520-528. doi: 10.1378/chest.14-0918. doi: 10.1378/chest.14-0918 URL
[35]	Huang HL, Huang WC, Lin KD, et al. Completion Rate and Safety of Programmatic Screening and Treatment for Latent Tuberculosis Infection in Elderly Patients With Poorly Controlled Diabetic Mellitus: A Prospective Multicenter Study. Clin Infect Dis, 2021, 73(6):e1252-e1260. doi: 10.1093/cid/ciab209. doi: 10.1093/cid/ciab209 URL
[36]	Rodriguez-Carlos A, Valdez-Miramontes C, Marin-Luevano P, et al. Metformin promotes Mycobacterium tuberculosis killing and increases the production of human β-defensins in lung epithelial cells and macrophages. Microbes Infect, 2020, 22(3):111-118. doi: 1016/j.micinf.2019.10.002. doi: S1286-4579(19)30127-3 pmid: 31689532
[37]	Degner NR, Wang JY, Golub JE, et al. Metformin Use Reverses the Increased Mortality Associated With Diabetes Mellitus During Tuberculosis Treatment. Clin Infect Dis, 2018, 66(2):198-205. doi: 10.1093/cid/cix819. doi: 10.1093/cid/cix819 URL
[38]	国家感染性疾病临床医学研究中心, 深圳市第三人民医院, 国家代谢性疾病临床医学研究中心, 等. 结核病与糖尿病共病的治疗管理专家共识. 中国防痨杂志, 2021, 43(1):12-22. doi: 10.3969/j.issn.1000-6621.2021.01.004. doi: 10.3969/j.issn.1000-6621.2021.01.004
[39]	Tegegne BS, Mengesha MM, Teferra AA, et al. Association between diabetes mellitus and multi-drug-resistant tuberculosis: evidence from a systematic review and meta-analysis. Syst Rev, 2018, 7(1):161. doi: 10.1186/s13643-018-0828-0. doi: 10.1186/s13643-018-0828-0 URL
[40]	Gao M, Gao J, Xie L, et al. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. Clin Microbiol Infect, 2021, 27(4):597-602. doi: 10.1016/j.cmi.2020.06.004. doi: 10.1016/j.cmi.2020.06.004 URL
[41]	Franke MF, Khan P, Hewison C, et al. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study. Am J Respir Crit Care Med, 2021, 203(1):111-119. doi: 10.1164/rccm.202001-0135OC. doi: 10.1164/rccm.202001-0135OC URL
[42]	Shi L, Gao J, Gao M, et al. Interim Effectiveness and Safety Comparison of Bedaquiline-Containing Regimens for Treatment of Diabetic Versus Non-Diabetic MDR/XDR-TB Patients in China: A Multicenter Retrospective Cohort Study. Infect Dis Ther, 2021, 10(1):457-470. doi: 10.1007/s40121-021-00396-9. doi: 10.1007/s40121-021-00396-9 pmid: 33515206
[43]	Wang W, Du Z, Ni M, et al. Aspirin enhances the clinical efficacy of anti-tuberculosis therapy in pulmonary tuberculosis in patients with type 2 diabetes mellitus. Infect Dis (Lond), 2020, 52(10):721-729. doi: 10.1080/23744235.2020.1778177. doi: 10.1080/23744235.2020.1778177
[44]	Kirwan DE, Chong DLW, Friedland JS. Platelet Activation and the Immune Response to Tuberculosis. Front Immunol, 2021, 12:631696. doi: 10.3389/fimmu.2021.631696. doi: 10.3389/fimmu.2021.631696 URL
[45]	Wang W, Du Z, Ni M, et al. Aspirin enhances the clinical efficacy of anti-tuberculosis therapy in pulmonary tuberculosis in patients with type 2 diabetes mellitus. Infect Dis (Lond), 2020, 52(10):721-729. doi: 10.1080/23744235.2020.1778177. doi: 10.1080/23744235.2020.1778177
[46]	Lin Y, Harries AD, Kumar AMV, et al. Tackling diabetes mellitus and tuberculosis: a new Union guide on the management of diabetes-tuberculosis. Int J Tuberc Lung Dis, 2019, 23(7):771-772. doi: 10.5588/ijtld.19.0119. doi: 10.5588/ijtld.19.0119 pmid: 31439106
[47]	邵立群, 赵飒. 营养治疗对2型糖尿病合并肺结核患者的影响. 中国现代药物应用, 2018, 12(14):185-186. doi: 10.14164/j.cnki.cn11-5581/r.2018.14.108. doi: 10.14164/j.cnki.cn11-5581/r.2018.14.108
[48]	Lee PH, Fu H, Lai TC, et al. Glycemic Control and the Risk of Tuberculosis: A Cohort Study. PLoS Med, 2016, 13(8):e1002072. doi: 10.1371/journal.pmed.1002072. doi: 10.1371/journal.pmed.1002072 URL